muc-1 peptide vaccine
Vaccineexperimental
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 1998 (NCT00008099)
Timeline
Indications
Mechanism of action
- Mucin-1Immunity, active
MUC1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- muc-1 peptide vaccine
- muc1 peptide vaccine
- peptide vaccine (muc-1)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06218303 | Phase 1 | Feb 7, 2024 | Breast Cancer Research Foundation, University of Pittsburgh |
| NCT02134925 | Phase 2 | Jun 1, 2014 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT01720836 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2012 | University of Pittsburgh |
| NCT00773097 | Phase 2 | Oct 1, 2008 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT00640861 | N/A | Aug 1, 2008 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00374049 | Phase 1 | Jun 1, 2006 | Oncovir, Inc., University of Pittsburgh |
| NCT00162500 | Phase 2 | Sep 11, 2005 | Hebrew University, Vaxil Therapeutics Ltd. |
| NCT00008099 | Phase 1 | May 1, 1998 | National Cancer Institute (NCI), University of Pittsburgh |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Pittsburgh | Academic/Hospital | 5 | 5 | 2 | 1998 |
| National Cancer Institute (NCI) | Government | 4 | 1 | 3 | 1998 |
| Mayo Clinic | Academic/Hospital | 2 | 1 | 2 | 2008 |
| Breast Cancer Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2006 |
| Vaxil Therapeutics Ltd. | For profit | 1 | 0 | 1 | 2005 |
7 organizations
Page 1 / 1